Latest Ratios: P/E Ratio -1029.4x · EV/EBITDA N/A · ROE N/A. (1999–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $146M | $93M | $59M | $296M | $676M | $737M | $549M | $549M | $264M | $321M | $359M |
| Enterprise Value | $478M | $425M | $113M | $313M | $576M | $503M | $504M | $511M | $224M | $424M | $413M |
| P/E Ratio → | -1029.41 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.28 | 0.82 | 0.57 | 1.90 | 6.90 | 2.49 | 6.22 | 3.66 | 7.17 | 7.48 | 15.89 |
| P/B Ratio | — | — | — | — | — | 15.39 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | 72.66 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.72 | 1.09 | 2.01 | 5.88 | 1.70 | 5.72 | 3.41 | 6.09 | 9.88 | 18.30 |
| EV / EBITDA | — | — | — | — | — | 15.47 | — | — | — | — | — |
| EV / EBIT | — | 8.15 | — | — | — | 13.61 | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 29.6% | 29.6% | -50.8% | -52.1% | -101.2% | 38.4% | -64.4% | -12.2% | -238.7% | -170.8% | -320.7% |
| Operating Margin | -18.0% | -18.0% | -116.4% | -102.1% | -183.0% | 8.7% | -133.0% | -46.7% | -336.6% | -242.1% | -476.1% |
| Net Profit Margin | 0.1% | 0.1% | -219.6% | -157.2% | -224.5% | -8.1% | -205.2% | -71.7% | -434.1% | -281.5% | -562.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | -49.9% | — | — | — | — | -803.7% |
| ROA | 0.1% | 0.1% | -84.1% | -67.6% | -50.0% | -7.0% | -97.8% | -73.8% | -116.2% | -81.7% | -63.6% |
| ROIC | — | — | — | — | — | — | — | — | — | -369.4% | -562.5% |
| ROCE | — | — | -383.2% | -112.9% | -67.2% | 13.1% | -199.1% | -138.2% | -164.8% | -104.8% | -65.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 1.22 | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | 1.79 | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | -4.88 | — | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | -7.18 | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 0.94 | 0.94 | -0.97 | -1.63 | -2.73 | 0.56 | -1.99 | -1.69 | -5.41 | -5.40 | -6.33 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.41 | 0.41 | 0.21 | 0.44 | 1.13 | 2.12 | 0.88 | 0.71 | 1.10 | 1.30 | 2.24 |
| Quick Ratio | 0.41 | 0.41 | 0.21 | 0.44 | 1.05 | 1.99 | 0.88 | 0.65 | 1.10 | 1.30 | 2.23 |
| Cash Ratio | 0.01 | 0.01 | 0.18 | 0.30 | 1.02 | 1.96 | 0.77 | 0.51 | 0.78 | 1.07 | 1.87 |
| Asset Turnover | — | 0.50 | 0.46 | 0.50 | 0.24 | 0.63 | 0.41 | 0.97 | 0.27 | 0.31 | 0.14 |
| Inventory Turnover | — | — | — | — | 14.26 | 8.94 | — | 22.69 | 2245.42 | 1460.86 | 1076.77 |
| Days Sales Outstanding | — | 5.85 | 1.44 | 60.33 | 10.21 | 1.87 | 4.79 | 39.63 | 9.31 | 9.66 | 183.56 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.1% | 0.1% | 0.0% | 1.7% | 0.6% | 0.2% | 0.0% | 0.0% | 0.0% | 0.2% | 0.2% |
| Total Shareholder Yield | 0.1% | 0.1% | 0.0% | 1.7% | 0.6% | 0.2% | 0.0% | 0.0% | 0.0% | 0.2% | 0.2% |
| Shares Outstanding | — | $30M | $21M | $18M | $14M | $11M | $9M | $7M | $6M | $5M | $4M |
Imminent liquidity exhaustion
According to recent market data, Agenus trades at a trailing P/E of -891.18, which, when combined with a forward P/E of 3.86, suggests that investors are pricing in highly speculative future milestone success rather than current fundamental earnings power or sustainable commercial growth trajectories.
The extreme disparity between trailing and forward multiples indicates that the market is heavily discounting the company's current clinical-stage status while pinning value on potential future regulatory catalysts. Investors should monitor whether these forward expectations are grounded in realistic probability-weighted outcomes or if they represent an overly optimistic view of the company's ability to monetize its pipeline.
As reported in financial statements, the company's ROIC has shown extreme volatility, reaching 23.6% in 2026Q1 only after significant non-recurring adjustments, which obscures the underlying reality that the firm has historically struggled to generate positive returns on its invested capital during its intensive R&D phase.
The erratic nature of these returns suggests that the company is not currently compounding value through its core operations but is instead reliant on episodic capital inflows. This pattern warrants further investigation into whether the firm can achieve a sustainable return profile once it transitions from a clinical-stage entity to a commercial-stage organization.
Based on quarterly filings, the company's asset turnover remains consistently low at approximately 0.11 to 0.16, reflecting a business model that is heavily weighted toward intangible clinical assets rather than revenue-generating physical infrastructure, which limits the firm's ability to optimize its working capital cycle efficiently.
The wide swings in days sales outstanding, which have fluctuated from 2 to 75 days, suggest that the timing of partner-driven milestone payments creates significant unpredictability in cash conversion. This lack of operational consistency makes it difficult for the company to manage its liquidity needs without relying on external financing.
As indicated by the most recent balance sheet data, the current ratio has plummeted to 0.38, a level that highlights a severe lack of liquid assets relative to near-term obligations and underscores the company's precarious financial position in the absence of immediate, non-dilutive capital injections.
The current liquidity profile suggests that the firm is operating with virtually no margin for error, leaving it highly vulnerable to any delays in clinical trial milestones or partner payments. Investors should monitor the company's ability to secure additional funding, as the current cash runway appears insufficient to support ongoing R&D operations.
The price-to-sales ratio is frequently misapplied to Agenus, as it fails to account for the lumpy, non-recurring nature of milestone-driven revenue, which can artificially deflate the multiple and create a false sense of value for a company that lacks a stable, recurring commercial revenue base.
Analysts should instead focus on cash-burn-adjusted valuation metrics or probability-weighted net present value models for the pipeline. Relying on P/S ratios in this context obscures the fundamental reality that the company's top-line is not yet a reliable indicator of long-term operational viability or future profitability.
Includes 30+ ratios · 27 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AGEN stock.
Agenus Inc.'s current P/E ratio is -1029.4x. This places it at the 50th percentile of its historical range.
Based on historical data, Agenus Inc. is trading at a P/E of -1029.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Agenus Inc. has 29.6% gross margin and -18.0% operating margin.